Yu-Pei Zhuang

Yu-Pei Zhuang

Auto-generated profile, based on publicly available information

Yu-Pei Zhuang

The First Affiliated Hospital of Guangdong Pharmaceutical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
WYWei-Chen Yuan
Wei-Chen Yuan
JZJie-Xiang Zhang
Jie-Xiang Zhang
HCHaibin Chen
Haibin Chen
YYYing Yuan
Ying Yuan
YZYu-Pei Zhuang
Yu-Pei Zhuang
STSang Tianqing
Sang Tianqing
Background: Cancer-associated fibroblasts (CAFs) represent the predominant stromal component within the tumour microenvironment (TME), exhibiting considerable heterogeneity and plasticity that significantly impact immune response and metabolic reprogramming within the TME, thereby influencing tumour progression. Consequently, investigating CAFs is of utmost importance. The objective of this study is to employ bibliometric analysis in order to evaluate the current state of research on CAFs and predict future areas of research and emerging trends.Methods: Conduct a comprehensive search for scholarly publications within the Web of Science Core Collection database, encompassing the time period from January 1, 2001, to December 31, 2022. Apply VOSviewer, CiteSpace, R software and Microsoft Excel for bibliometric analysis and visualisation.Results: This study involved a comprehensive analysis of 5,925 publications authored by 33,628 individuals affiliated with 4,978 institutions across 79 countries/regions. These publications were published in 908 journals, covering 14,495 keywords and 203,947 references. Notably, there was a significant increase in articles published between 2019 and 2022. China had the highest count of articles, while the United States emerged as the most frequently cited country. The primary research institutions in this field were Shanghai Jiao Tong University, Harvard University, and the University of Texas MD Anderson Cancer Center. Sotgia, Federica and Lisanti, Michael P from the University of Manchester, and Martinet, Wim from the University of Antwerp were the most prolific and highly cited authors. The journal Cancers had the highest number of publications, while Cancer Research was the most frequently cited journal. Molecular, biology, immunology, medicine and genetics were the main research disciplines in the field of CAFs. Key directions in CAFs research encompassed the study of transforming growth factor-β, Fibroblast Activation Protein, breast cancer, as well as growth and metastasis. The findings from the analysis of keyword co-occurrence and literature co-citation have revealed several emerging hotspots and trends within the field of CAFs. These include STAT3, multidrug resistance, pancreatic ductal adenocarcinoma, pan-cancer analysis, preclinical evaluation, ionizing radiation, and gold nanoparticles.Conclusion: Targeting CAFs is anticipated to be a novel and effective strategy for cancer treatment. This study provides a comprehensive overview of the existing research on CAFs from 2001 to 2022, utilizing bibliometric analysis. The study identified the prominent areas of investigation and anticipated future research directions, with the aim of providing valuable insights and recommendations for future studies in the field of CAFs.

6 December 2021 in Open Medicine
Verified
Journal Article
Open access
PDF file
YZYu-Pei Zhuang
Yu-Pei Zhuang
SWSi-Qi Wang
Si-Qi Wang
ZPZhao-Yu Pan
Zhao-Yu Pan
HZHao-Jie Zhong
Hao-Jie Zhong
XHXing-Xiang He
Xing-Xiang He
Objectives This study aimed to investigate the differences in complications between hepatitis B virus (HBV)-related and alcohol-related cirrhoses. Methods Medical records of patients with HBV-related and alcohol-related cirrhoses treated from January 2014 to January 2021 were, retrospectively, reviewed. The unadjusted rate and adjusted risk of cirrhotic complications between the two groups were assessed. Results The rates of hepatocellular carcinoma (HCC) and hypersplenism were higher in HBV-related cirrhosis (both P < 0.05), whereas the rates of hepatic encephalopathy (HE) and acute-on-chronic liver failure (ACLF) were higher in alcohol-related cirrhosis (both P < 0.05). After adjusting for potential confounders, HBV-related cirrhotic patients had higher risks of HCC (odds ratio [OR] = 34.06, 95% confidence interval [CI]: 4.61–251.77, P = 0.001) and hypersplenism (OR = 2.29, 95% CI: 1.18–4.42, P = 0.014), whereas alcohol-related cirrhotic patients had higher risks of HE (OR = 0.22, 95% CI: 0.06–0.73, P = 0.013) and ACLF (OR = 0.30, 95% CI: 0.14–0.73, P = 0.020). Conclusion Cirrhotic patients with different etiologies had different types of complications: HBV-related cirrhotic patients exhibited increased risks of HCC and hypersplenism and alcohol-related cirrhotic patients more readily developing HE and ACLF.

24 October 2021 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
HZHao-Jie Zhong
Hao-Jie Zhong
YZYu-Pei Zhuang
Yu-Pei Zhuang
YZYi-Ting Zhang
Yi-Ting Zhang
SXShun-Peng Xu
Shun-Peng Xu
MHMing-Fan Hong
Ming-Fan Hong
XHXing-Xiang He
Xing-Xiang He
Complications affect the outcome of patients with cirrhosis. The favorable prognosis of patients with Wilson disease (WD)-related cirrhosis suggests that its complications differ from those of hepatitis B virus (HBV) infection-related cirrhosis. We aimed to delineate the differences in complications between WD-related and HBV-related cirrhosis. The electronic-medical data from patients with WD-related and HBV-related cirrhosis were extracted and analyzed. In total, 211 patients with WD-related cirrhosis and 374 patients with HBV-related cirrhosis were enrolled. Most patients with WD progressed to cirrhosis 10 years. Patients with WD-related cirrhosis had a markedly lower prevalence of ascites (8.5% vs. 38.5%), gastroesophageal varices/variceal bleeding (13.3% vs. 47.6%), renal impairment (0 vs. 7.6%) and primary liver cancer (0 vs. 39.3%; all P < 0.001) than those with HBV-related cirrhosis. After adjustment for potential confounders, patients with WD-related cirrhosis carried a lower risk of varices/variceal bleeding. Although patients with WD progressed to cirrhosis much faster, the prevalence of complications from WD-related cirrhosis was low. Patients with WD-related cirrhosis were less likely to develop gastroesophageal varices/variceal bleeding than those with HBV-related cirrhosis.

3 October 2021
Verified
Preprint
Open access
YZYu-Pei Zhuang
Yu-Pei Zhuang
YZYi-Ting Zhang
Yi-Ting Zhang
HZHao-Jie Zhong
Hao-Jie Zhong
XHXing-Xiang He
Xing-Xiang He
Objective To investigate the association between intestinal permeability and severity of nonalcoholic fatty liver disease (NAFLD), and the value of intestinal permeability in predicting the efficacy of metabolic therapy for NAFLD. Methods Disease severity was compared between patients with normal and elevated intestinal permeability; correlations between D-lactate and different NAFLD parameters were analyzed; and the effects of metabolic therapy on NAFLD patients with normal and elevated intestinal permeability were evaluated. Results A total of 190 patients with NAFLD were enrolled. NAFLD patients with elevated intestinal permeability had significantly higher levels of liver test parameters, liver ultrasonographic fat attenuation parameter, triglyceride, homeostasis model assessment of insulin resistance value and diamine oxidase (all P˂0.05) than NAFLD patients with normal intestinal permeability. Further, serum D-lactate levels were positively correlated with alanine transaminase, aspartate transaminase, gamma-glutamyl transpeptidase, total bilirubin, indirect bilirubin, fat attenuation parameter, triglyceride, and diamine oxidase (all P˂0.05). Moreover, NAFLD patients with elevated intestinal permeability showed less improvement in TG levels (P=0.014) after metabolic therapy. Conclusion Intestinal permeability correlates with the disease severity in patients with NAFLD. Moreover, intestinal permeability may have value for predicting the efficacy of metabolic therapy for NAFLD patients.

31 January 2024
Verified
Preprint
Open access
YZYu-Pei Zhuang
Yu-Pei Zhuang
SWSi-Qi Wang
Si-Qi Wang
ZPZhao-Yu Pan
Zhao-Yu Pan
HZHao-Jie Zhong
Hao-Jie Zhong
XHXing-Xiang He
Xing-Xiang He
Rationale, aims and objectives: Chronic hepatitis B virus (HBV) infection and alcoholism are the leading cirrhotic etiologies. Cirrhosis cases caused by different etiologies have different clinical features, which leads to different clinical outcomes. This study aimed to investigate the differences in complications between HBV- and alcohol-related cirrhosis. Methods: Medical records of hospitalized patients with HBV- or alcohol-related cirrhosis treated from January 2014 to January 2021 were retrospectively reviewed. The unadjusted rate and adjusted risk of cirrhotic complications between the two groups were assessed. Results: The rates of hepatocellular carcinoma (HCC) and hypersplenism were notably higher in HBV-related cirrhosis (HCC: 39.55% vs 1.45%, P < 0.001; hypersplenism: 45.84% vs 28.99%, P = 0.009), whereas the rates of hepatic encephalopathy (HE) and acute-on-chronic liver failure (ACLF) were higher in alcohol-related cirrhosis (HE: 15.94% vs 4.49%, P = 0.001; ALCF: 7.25% vs 2.28%, P = 0.040). After adjusting for potential confounders, HBV-related cirrhotic patients still had higher risks of HCC (odds ratio [OR] = 34.06, 95% confidence interval [CI]: 4.61–251.77, P = 0.001) and hypersplenism (OR = 2.29, 95% CI: 1.18–4.42, P = 0.014), while alcohol-related cirrhotic patients still had higher risks of HE (OR= 0.22, 95% CI: 0.06–0.73, P = 0.013) and ACLF (OR = 0.30, 95% CI: 0.14–0.73, P = 0.020). Conclusion: HBV-related cirrhotic patients had increased risks of HCC and hypersplenism, while alcohol-related cirrhotic patients more readily developed HE and ACLF.